Abstract: Observe To effect of ETV dispersible tablets combined therapy with compound glycyrrhizin acid treatment for compensatory phase active hepatitis B with cirrhosis and to explore its action mechanism, in order to further improve the compensatory phase active hepatitis B with cirrhosis provide evidence for clinical efficacy. Methods Total of 60 patients with compensatory phase active hepatitis B cirrhosis were randomly divided into treatment group (30 cases) and control group (30 cases). Patients in two groups were given ETV dispersible tablets 0.5 mg once time, once-a-day, morning oral on an empty stomach, and patients in treatment group were also applied with joint compound glycyrrhizin glucoside piece of 75 mg once time, 3 times a day at the same time. Patients in both groups were treated for 48 weeks. Observed the changes of two groups before and after treatment in patients with liver function, serum liver fibrosis indexes and liver stiffness index, serum virology (HBV DNA, HBeAg and anti-HBe) indicators. Using the color doppler ultrasound examination compare the inner diameter changes of the liver, spleen, and portal vein diameter. Results After 48 weeks, the index of two groups of patients with liver function (ALT, AST, ALB and TBil), serum liver fibrosis indexes (HA, LN, PC Ⅲ, Ⅳ-C) and hepatic hardness index comparison differences had statistical significance (both P = 0.000). Two groups of patients before and after treatment serum HBV DNA level comparative difference had statistical significance (both P = 0.000). But the comparative differences between groups had no statistical significance (P = 0.490, 0.630). After 48 weeks, the control group in HBeAg below the detection limit is 30.8%, the ratio of serological conversion rate 23.1%, and the treatment group in HBeAg below the detection limit is 50.0%, the ratio of serological conversion rate of 35.7%. The ratio of two groups of patients with HBeAg below the detection limit and serological conversion rate comparison, difference had statistical significance (P = 0.029, 0.040). In two groups before and after treatment in patients with portal vein diameter. The spleen length to diameter, the thickness of the spleen, spleen vein width comparative differences had no statistical significance (P = 0.830, 0.350, 0.870, 0.490). Conclusions ETV combined compound glycyrrhizic acid glycosides have synergy effect on treatment for patients with compensatory phase of hepatitis B cirrhosis of the liver, its mechanism may be related to anti-HBV, resisting hepatic fibrosis, improving liver function, immune regulation and so on.